BMEYE and PULSION Sign Licensing AgreementBy Bmeye B.v., PRNE
Wednesday, December 1, 2010
BMEYE's Breakthrough Totally Noninvasive Blood Pressure and Cardiac Output Technology Will be Incorporated Into PULSION's Next Generation Patient Monitors
AMSTERDAM, December 2, 2010 - BMEYE B.V., the innovators of a totally noninvasive combined beat-to-beat
blood pressure and cardiac output monitoring system, and PULSION Medical
Systems AG, a leading specialist in minimally invasive critical care and
cardiovascular patient monitoring, have reached agreement on a worldwide,
non-exclusive license which allows BMEYE's technology to be integrated into
PULSION's next generation hemodynamic patient monitoring solution. BMEYE will
develop a custom made OEM module for PULSION Medical Systems AG.
The BMEYE technology offers one of the most advanced cardiovascular
monitoring capabilities available today. It utilizes a finger cuff to capture
and continuously measure beat-to-beat blood pressure and cardiac output
totally noninvasively. This detailed data allows clinicians to predict and
proactively address the early signs of hemodynamic instability during
critical situations rather than reacting on late indicators and effects.
PULSION's PiCCO - Technology permits comprehensive and low-risk
monitoring of cardiovascular function in critically ill patients in the
intensive-care environment. PiCCO has become the leading hemodynamic monitor
in ICUs in Europe, where the high-risk right-heart catheter method is being
increasingly put under pressure. PiCCO monitoring provides a wide-range of
information to the physician including precise calibrated real-time cardiac
output, volume variables and parameters for lung oedema diagnostics to
effectively perform early goal directed therapies.
"Part of the BMEYE strategy is to develop the OEM channel in hemodynamic
and patient monitoring and to make our technology broadly available for
integrated solutions besides our standalone sales channel," stated Rob de
Ree, CEO of BMEYE." As such PULSION is a very valuable partner as a European
leader in the intensive care field."
PULSION's CEO, Patricio Lacalle stated "The integration of BMEYE's
noninvasive technology is another important step in building a consistent
product portfolio to help patients in a broad range of different acute
situations with increased risk or impaired function of the cardiovascular
system. We are able to provide a flexible solution for hospitals by covering
non-invasive and minimally invasive hemodynamic monitoring, as well as the
sophisticated and highly precise PiCCO monitoring technology."
BMEYE, a Dutch company based in Amsterdam, The Netherlands, develops
innovative medical devices with broad application in clinical settings that
require cardiovascular monitoring. Specifically, BMEYE produces patient
monitors that noninvasively measure continuous blood pressure and cardiac
output. BMEYE's mission: BMEYE is the premier provider and will set the
standard of noninvasive, beat-to-beat, user-friendly cardiovascular
monitoring systems, to improve patient care and reduce healthcare costs.
Media Contacts: Rob de Ree, BMEYE B.V., +31-207512410
Tags: Amsterdam, BMEYE B.V., December 2, Netherlands